Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-401-9975
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.52 million
Profitability
Miscellaneous
Employees74
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Synlogic (NASDAQ:SYBX) Frequently Asked Questions
What is Synlogic's stock symbol?
Synlogic trades on the NASDAQ under the ticker symbol "SYBX."
When did Synlogic's stock split? How did Synlogic's stock split work?
Synlogic's stock reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.
How were Synlogic's earnings last quarter?
Synlogic Inc (NASDAQ:SYBX) posted its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.04. The biotechnology company had revenue of $0.35 million for the quarter, compared to analysts' expectations of $0.96 million. Synlogic had a negative return on equity of 34.75% and a negative net margin of 1,844.96%. View Synlogic's Earnings History.
When is Synlogic's next earnings date?
What price target have analysts set for SYBX?
8 equities research analysts have issued 1-year price objectives for Synlogic's stock. Their predictions range from $2.00 to $25.00. On average, they anticipate Synlogic's stock price to reach $18.3750 in the next year. This suggests a possible upside of 426.5% from the stock's current price. View Analyst Price Targets for Synlogic.
What is the consensus analysts' recommendation for Synlogic?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synlogic.
What are Wall Street analysts saying about Synlogic stock?
Here are some recent quotes from research analysts about Synlogic stock:
- 1. According to Zacks Investment Research, "Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. " (8/14/2019)
- 2. HC Wainwright analysts commented, "We calculate an enterprise value of $820M, comprised of $620M for SYNB1020 in UCD and hyperammonemia and I/O portfolio. This yields a price objective of $22.00 per share, with approximately 37M fully-diluted shares outstanding as of mid-2020 (including exercise of approximately 2.5M outstanding options and all of the roughly 2.5M pre-funded warrants previously issued in the last private placement transaction). Risks include, but are not limited to: (1) feasibility issues with bridging the liquid to the solid oral formulation; (2) negative results from early trials; (3) slower-than-anticipated clinical testing; and (4) inability to obtain regulatory approvals." (8/12/2019)
- 3. Chardan Capital analysts commented, "We continue to be encouraged by the preclinical studies (1, 2) and the healthy volunteer data which demonstrated measurable effects on biomarkers of engineered bacterial metabolism even in the context of functional host metabolic processes. We also see the work done to standardize the measurement of key analytes across trial sites as valuable groundwork for robust readouts. With respect to anticipated therapeutic thresholds targeted for these products, both are aiming for fairly moderate impacts on toxic metabolite levels, specifically a 15%-20% lowering of blood ammonia in the hepatic encephalopathy patients after SYNB1020 treatment and a doubling (from ~6 g to ~12 g) of protein tolerated in PKU patients treated with SYNB1618. Of note, the trial of SYNB1618 is not powered to detect significant differences Phe lowering, but will inform future endpoints and target profiles." (3/12/2019)
Has Synlogic been receiving favorable news coverage?
News headlines about SYBX stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Synlogic earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Synlogic.
Are investors shorting Synlogic?
Synlogic saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 1,327,200 shares, an increase of 9.9% from the June 30th total of 1,207,300 shares. Based on an average daily trading volume, of 192,700 shares, the days-to-cover ratio is currently 6.9 days. Approximately 8.2% of the company's stock are short sold. View Synlogic's Current Options Chain.
Who are some of Synlogic's key competitors?
Some companies that are related to Synlogic include Rocket Pharmaceuticals (RCKT), DiaMedica Therapeutics (DMCAF), Karyopharm Therapeutics (KPTI), Akebia Therapeutics (AKBA), Kiniksa Pharmaceuticals (KNSA), Aurinia Pharmaceuticals (AUPH), Synthorx (THOR), Advanz Pharma (CXRXF), Karuna Therapeutics (KRTX), Endo International (ENDP), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), Viking Therapeutics (VKTX), INDIVIOR PLC/S (INVVY) and Aptorum Group (APM).
What other stocks do shareholders of Synlogic own?
Who are Synlogic's key executives?
Synlogic's management team includes the folowing people:
- Dr. Peter Barrett, Exec. Chairman (Age 66)
- Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)
- Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Pres, CEO, Chief Medical Officer & Director (Age 43)
- Prof. Timothy K. Lu, Co-Founder
- Dr. James J. Collins, Co-Founder
Who are Synlogic's major shareholders?
Synlogic's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.15%), Vanguard Group Inc. (2.43%), JPMorgan Chase & Co. (0.88%), Northern Trust Corp (0.64%), Bank of New York Mellon Corp (0.22%) and Charles Schwab Investment Management Inc. (0.15%). View Institutional Ownership Trends for Synlogic.
Which major investors are selling Synlogic stock?
Which major investors are buying Synlogic stock?
SYBX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Parametric Portfolio Associates LLC, Charles Schwab Investment Management Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Synlogic.
How do I buy shares of Synlogic?
Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synlogic's stock price today?
One share of SYBX stock can currently be purchased for approximately $3.49.
How big of a company is Synlogic?
Synlogic has a market capitalization of $110.70 million and generates $2.52 million in revenue each year. The biotechnology company earns $-48,440,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. Synlogic employs 74 workers across the globe.View Additional Information About Synlogic.
What is Synlogic's official website?
How can I contact Synlogic?
Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]
MarketBeat Community Rating for Synlogic (NASDAQ SYBX)
MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote "Outperform" if you believe SYBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
